semaj83/ctmatch_classification huggingface dataset:
Patient description: A group of 14 humanitarian service workers is preparing a trip to the Amazon Rainforest region in Brazil. All the members of the group have traveled on multiple occasions and have up-to-date vaccine certificates. Malaria Chemoprophylaxis is indicated but three of the women are in different stages of pregnancy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acute Uncomplicated P. Falciparum Malaria Patients were eligible for if they met all of the following Male or female aged 18 or older (prior to Amendment 1: more than 2 years old) Non-immune patients suffering from acute uncomplicated P. falciparum malaria, or mixed infection including P. falciparum, with parasitemia of less than or equal to 2% asexual P.falciparum parasites, confirmed by microscopy using Giemsa-stained thick film Non-immune patients were regarded as those who had not spent the first five years of their life, nor the last five years in a malaria endemic area, and did not have acute P. falciparum malaria diagnosed during those past five years Non-immune patients who had received prophylaxis with anti-malarials (excluding halofantrine) were included only if clear progression of acute P. falciparum infection was documented Female patients were eligible to participate in the study if they were of non-childbearing potential or had a negative pregnancy test (urine or serum) at screening, and using an acceptable contraceptive method Patients, who had been informed of the study procedures and medication, and had given written informed consent and were willing to comply with the study protocol  Patients were to be excluded from participation if they met any of the following Known hypersensitivity to artemether or lumefantrine Signs/symptoms indicative of severe/complicated malaria according to the WHO classification (e.g. cerebral malaria, see Post-text supplement 1) Treatment with artemisinin derivatives within the previous 7 days Concurrent administration of other treatment / prophylaxis for malaria Concurrent administration of medications with potential hemolytic effects Patients taking any drug metabolized by cytochrome isoenzymes CYP3A4 or CYP2D6 Received any other investigational drugs in the last 4 weeks before entry into the study Severe cardiac impairment (i.e. evidence of existing cardiac conduction defect or overt symptoms of cardiac dysfunction or abnormalities of baseline ECG not associated with acute malaria); clinically relevant bradycardia or congestive cardiac failure with reduced left ventricular ejection fraction; pre-existing prolongation of the QT interval; history of symptomatic cardiac arrhythmias Having received halofantrine or any other drug known to influence cardiac function within 4 weeks prior to Screening visit or taking other drugs that are known to prolong the QT interval, including class IA and III antiarrhythmics, neuroleptics, antidepressive agents, certain antibiotics (including some macrolides, fluoroquinolones, imidazole, and triazole antifungal agents), certain non-sedating antihistaminics (terfenadine, astemizole) and cisapride
Patient description: A group of 14 humanitarian service workers is preparing a trip to the Amazon Rainforest region in Brazil. All the members of the group have traveled on multiple occasions and have up-to-date vaccine certificates. Malaria Chemoprophylaxis is indicated but three of the women are in different stages of pregnancy.

Clinical trial eligibility criteria: eligible ages (years): 14.0-45.0,  Anaemia Malaria Primigravida Secundigravida Permanent resident Hemoglobin (Hb) > 7 g/dl  Hb < 7 g/dl Allergy to sulpha Multiple pregnancy Chronic diseases
Patient description: A group of 14 humanitarian service workers is preparing a trip to the Amazon Rainforest region in Brazil. All the members of the group have traveled on multiple occasions and have up-to-date vaccine certificates. Malaria Chemoprophylaxis is indicated but three of the women are in different stages of pregnancy.

Clinical trial eligibility criteria: eligible ages (years): 0.25-4.917,  Malaria For original trial: Children aged 3-59 months present in participating villages For follow-up: Children who were in original trial for at least 1 year  For original trial: None For follow-up: Children with mental or physical disabilities who were unable to do cognitive tests
Patient description: A group of 14 humanitarian service workers is preparing a trip to the Amazon Rainforest region in Brazil. All the members of the group have traveled on multiple occasions and have up-to-date vaccine certificates. Malaria Chemoprophylaxis is indicated but three of the women are in different stages of pregnancy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  HIV Infections Permanent residents of the Luanshya district Males and non pregnant adults between 18 and 50 years old Having a CD4 cell count of least 350 perµL at enrolment HIV sero-status determined at the VCT of the health center No obvious underlying disease at time of enrolment Signed informed consent  HIV stage III or IV following the WHO classification (see attached documents regarding policy in Zambia) Evidence of underlying chronic diseases (cardiac, renal, hepatic, malnutrition, TB) Intent to move out of the study catchment area during the study period History of allergy to MQ (or related drugs) or sulfa drugs Chorionic gonadotrophic hormone in urine or obvious pregnancy
Patient description: A group of 14 humanitarian service workers is preparing a trip to the Amazon Rainforest region in Brazil. All the members of the group have traveled on multiple occasions and have up-to-date vaccine certificates. Malaria Chemoprophylaxis is indicated but three of the women are in different stages of pregnancy.

Clinical trial eligibility criteria: eligible ages (years): 5.0-60.0,  Malaria Age: 5 years old Fever (axillary temperature equal or higher than 37,5 °C) or history of fever in the previous 24 hours Monoinfection with P. falciparum, with parasitic density between 1,000 and 200,000 par/µl Informed consent provided by patient or parent or legal tutor  Mixed malaria infection Pregnancy or breastfeeding to child ≤ 6 months of age One or more danger signs or any sign of severe or complicated malaria A concomitant severe disease History of treatment with mefloquine in the last 60 days or chloroquine, primaquine or quinine within the 14 days before the present episode History of neuropsychiatric disease History of hypersensitivity reactions to artemisinins or mefloquine History of splenectomy
Patient description: A group of 14 humanitarian service workers is preparing a trip to the Amazon Rainforest region in Brazil. All the members of the group have traveled on multiple occasions and have up-to-date vaccine certificates. Malaria Chemoprophylaxis is indicated but three of the women are in different stages of pregnancy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Falciparum Malaria Age > 18 and < 45 years healthy volunteers (males or females) General good health based on history and clinical examination All volunteers have to sign the informed consent form Negative pregnancy test Use of adequate contraception for females Reachable by phone during the whole study period Volunteer agrees to inform the general practitioner and agrees to sign a request for medical information concerning contra-indications for participation in the trial  History of malaria or residence in malaria endemic areas within the past six months Positive serology for P. falciparum Previously participated in any malaria vaccine study Symptoms, physical signs and laboratory values suggestive of systemic disorders, including renal, hepatic, cardiovascular, pulmonary, skin, immunodeficiency, psychiatric and other conditions, which could interfere with the interpretation of the study results or compromise the health of the volunteers Cardiovascular risk >10% according to European guidelines, taking into account sex, age, cholesterol, weight, smoking habits, blood pressure, diabetes Any laboratory abnormalities on screened blood samples beyond the normal range, as defined at UMC St Radboud. Positive HIV, HBV or HCV tests Volunteers should not be enrolled in any other clinical trial during the whole trial period Volunteers should not receive chronic medication, especially immunosuppressive agents (steroids, immunomodulating or immunosuppressive drugs) during the three months preceding the screening visit or during the study period Pregnant or lactating women Volunteers unable to give written informed consent
Patient description: A group of 14 humanitarian service workers is preparing a trip to the Amazon Rainforest region in Brazil. All the members of the group have traveled on multiple occasions and have up-to-date vaccine certificates. Malaria Chemoprophylaxis is indicated but three of the women are in different stages of pregnancy.

Clinical trial eligibility criteria: eligible ages (years): 15.0-45.0,  Malaria Parasitaemia Birth Weight Anaemia Pregnant women of all parities Second trimester  Severely ill pregnant women Pregnant women in first trimester
Patient description: A group of 14 humanitarian service workers is preparing a trip to the Amazon Rainforest region in Brazil. All the members of the group have traveled on multiple occasions and have up-to-date vaccine certificates. Malaria Chemoprophylaxis is indicated but three of the women are in different stages of pregnancy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-0.003,  Malaria Anemia Born in San Francis Designated District Hospital of Ifakara  Obvious severe congenital malformation such as: spina bifida, hydrocephalus or anencepahlus Twins Birth weight < 1,5 kg Clinical signs of cerebral asphyxia Clinical signs of neonatal or congenital infection Mother unreliable (deaf, mentally handicapped)
Patient description: A group of 14 humanitarian service workers is preparing a trip to the Amazon Rainforest region in Brazil. All the members of the group have traveled on multiple occasions and have up-to-date vaccine certificates. Malaria Chemoprophylaxis is indicated but three of the women are in different stages of pregnancy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-40.0,  Length of Pregnancy Prolongation in Hours All patients admitted with the diagnosis of preterm labor between 24 0/7 and 33 6/7 weeks gestation. Preterm labor will be defined by regular contractions and/or cervical change from last documented exam Cervical exam 4 cm or greater Intact membranes  Multiple gestation (>2) Clinical evidence of chorioamnionitis, such as maternal fever, uterine tenderness, fetal tachycardia Lethal fetal anomaly Persistent vaginal bleeding, abruption, or placenta previa Rupture of membranes Maternal illness or fetal indication requiring delivery Inability to give informed consent Serious allergy to study medications. GI discomfort will not be considered a drug allergy
Patient description: A group of 14 humanitarian service workers is preparing a trip to the Amazon Rainforest region in Brazil. All the members of the group have traveled on multiple occasions and have up-to-date vaccine certificates. Malaria Chemoprophylaxis is indicated but three of the women are in different stages of pregnancy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Orthopedic Disorders Unwillingness to sign informed consent  Pregnancy
Patient description: A group of 14 humanitarian service workers is preparing a trip to the Amazon Rainforest region in Brazil. All the members of the group have traveled on multiple occasions and have up-to-date vaccine certificates. Malaria Chemoprophylaxis is indicated but three of the women are in different stages of pregnancy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Malaria in Pregnancy Female First or second trimester of pregnancy First or second pregnancy Resident in the study area  Refuse to give informed consent
Patient description: A group of 14 humanitarian service workers is preparing a trip to the Amazon Rainforest region in Brazil. All the members of the group have traveled on multiple occasions and have up-to-date vaccine certificates. Malaria Chemoprophylaxis is indicated but three of the women are in different stages of pregnancy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Malaria in Pregnancy HIV Infections Confirmed HIV seropositivity Permanent residency in the study catchment's area Confirmed pregnancy, gestational age< 28 weeks More than 18 years of age Karnofsky index ≥80 Willingness to deliver at the hospital Written informed consent  History of allergy to study drugs : sulpha drugs, mefloquine, quinine History or presence of major illnesses : severe renal disease , severe hepatic disease, severe neuropsychiatric disease Mefloquine or halofantrine received within the 4 weeks prior to enrolment
Patient description: A group of 14 humanitarian service workers is preparing a trip to the Amazon Rainforest region in Brazil. All the members of the group have traveled on multiple occasions and have up-to-date vaccine certificates. Malaria Chemoprophylaxis is indicated but three of the women are in different stages of pregnancy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Malaria A male or non-pregnant, non-lactating female 18 to 50 years of age (inclusive) at the time of screening Free of clinically significant health problems Baseline ECG before entering into the study Available to participate for duration of study (approximately 4 months, not including screening period) If the participant is female, not pregnant or lactating and willing to use contraception to prevent pregnancy BMI between 19 and 30  History of malaria or travel to a malarious country within the previous 12 months History of participation in a study in which potential exposure to malaria or vaccination against malaria occurred Planned travel to malarious areas during the study period History of malaria chemoprophylaxis within 60 days prior to time of study entry Chronic use of antibiotics with anti-malarial effects Chronic use (defined as more than 14 days)of immunosuppressants or other immune-modifying drugs within six months of study entry Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination, ECG or laboratory screening tests Significant unexplained anemia History of sickle cell disease or sickle cell trait
Patient description: A group of 14 humanitarian service workers is preparing a trip to the Amazon Rainforest region in Brazil. All the members of the group have traveled on multiple occasions and have up-to-date vaccine certificates. Malaria Chemoprophylaxis is indicated but three of the women are in different stages of pregnancy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Malaria Subject is willing and able to give informed consent for participation in the study Healthy, non pregnant adult aged 18 years Resident in or near Oxford for the duration of the challenge study Seropositive for CMV and EBV Female subjects of child bearing potential must be willing to ensure that they practice effective contraception during the study Males must be willing to use barrier contraception from day of first vaccination onwards until 3 months after the second vaccination Able (in the Investigator's opinion) and willing to comply with all study requirements Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study Agreement to permanently refrain from blood donation  Any deviation from the normal range in biochemistry or haematology blood tests or in urine analysis as defined in Appendix B Female patient/subject who is pregnant, lactating or planning pregnancy during the course of the study Healthy volunteers who have participated in another research study involving an investigational product in the past 12 weeks Subjects who have previously received an investigational malaria vaccine History of malaria chemoprophylaxis with chloroquine within 5 months prior to the planned challenge, with Lariam within 6 weeks prior to the challenge, and Riamet® within 2 weeks prior to the challenge Travel to a malaria endemic area within the previous 6 months Planned travel to malarious areas during the study period Any history of malaria Contraindication to both anti-malarial drugs (Riamet® and chloroquine) concomitant use of other drugs known to cause QT-interval prolongation, ( e.g. macrolides, quinolones, amiodarone etc)
Patient description: A group of 14 humanitarian service workers is preparing a trip to the Amazon Rainforest region in Brazil. All the members of the group have traveled on multiple occasions and have up-to-date vaccine certificates. Malaria Chemoprophylaxis is indicated but three of the women are in different stages of pregnancy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Influenza Age 18 -65 Have the ability to provide informed consent If a woman of child-bearing potential, willing to use contraception for the period of the trial  Acute influenza-like illness at screening History of psoriasis, porphyria cutanea tarda, epilepsy, myasthenia gravis, myopathy of any cause, cardiac arrhythmias, or serious hepatic or renal disease Pregnancy or breast feeding Current use of medication with known serious hepatotoxic effects Current use of medication with known serious interaction with CQ: amiodarone, anticonvulsants, ciclosporin, digoxin, mefloquine, moxifloxacin Current severe depression (as indicated by current use of antidepressant medication) Known serious retinal disease Current or recent (within the past 30 days) participation in any other clinical intervention trial Known G6PD deficiency Vaccination for influenza (seasonal or H1N1 strain) within the 3 months prior to screening
Patient description: A group of 14 humanitarian service workers is preparing a trip to the Amazon Rainforest region in Brazil. All the members of the group have traveled on multiple occasions and have up-to-date vaccine certificates. Malaria Chemoprophylaxis is indicated but three of the women are in different stages of pregnancy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-35.0,  Plasmodium Falciparum Malaria Age > 18 and < 35 years healthy volunteers (males or females) Good health based on history and clinical examination Negative pregnancy test Use of adequate contraception for females All volunteers must sign the informed consent form demonstrating their understanding of the meaning and procedures of the study Volunteer agrees to inform the general practitioner and agrees to sign a request to release medical information concerning contra-indications for participation in the study Willingness to undergo a Pf mosquito challenge For volunteers not living in Leiden: agreement to stay in a hotel room close to the trial center during a part of the study (Day 5 after challenge till 3 days after treatment) Reachable (24/7) by mobile phone during the whole study period Living with a third party that could contact the clinicians in case of alteration of consciousness or agreement to stay in a hotel room close to the trial center during a part of the study (Day 5 after challenge till 3 days after treatment)  History of malaria Plans to travel to malaria endemic areas during the study period Plans to travel outside of the Netherlands during the challenge period Previous participation in any malaria vaccine study and/or positive serology for Pf Symptoms, physical signs and laboratory values suggestive of systemic disorders including renal, hepatic, cardiovascular, pulmonary, skin, immunodeficiency, psychiatric, and other conditions which could interfere with the interpretation of the study results or compromise the health of the volunteers History of diabetes mellitus or cancer (except basal cell carcinoma of the skin) History of arrhythmias or prolonged QT-interval Positive family history in 1st and 2nd degree relatives for cardiac disease < 50 years old An estimated, ten year risk of fatal cardiovascular disease of ≥5%, as estimated by the Systematic Coronary Risk Evaluation (SCORE) system Clinically significant abnormalities in electrocardiogram (ECG) at screening
Patient description: A group of 14 humanitarian service workers is preparing a trip to the Amazon Rainforest region in Brazil. All the members of the group have traveled on multiple occasions and have up-to-date vaccine certificates. Malaria Chemoprophylaxis is indicated but three of the women are in different stages of pregnancy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-35.0,  Plasmodium Falciparum Malaria Age > 18 and < 35 years healthy volunteers (males or females) Good health based on history and clinical examination Negative pregnancy test Use of adequate contraception for females All volunteers must sign the informed consent form demonstrating their understanding of the meaning and procedures of the study Volunteer agrees to inform the general practitioner and agrees to sign a request to release medical information concerning contra-indications for participation in the study Willingness to undergo a Pf mosquito or blood stage challenge For volunteers not living in Nijmegen: agreement to stay in a hotel room close to the trial center during a part of the study (for groups 1 and 3 from challenge day till 3 days after treatment, for groups 2 and 4 from 5 days after challenge till 3 days after treatment) Reachable (24/7) by mobile phone during the whole study period Living with a third party that could contact the clinicians in case of alteration of consciousness or agreement to stay in a hotel room close to the trial center during a part of the study (for groups 1 and 3 from challenge day till 3 days after treatment, for groups 2 and 4 from 5 days after challenge till 3 days after treatment)  History of malaria Plans to travel to malaria endemic areas during the study period Plans to travel outside of the Netherlands during the challenge period Previous participation in any malaria vaccine study and/or positive serology for Pf Symptoms, physical signs and laboratory values suggestive of systemic disorders including renal, hepatic, cardiovascular, pulmonary, skin, immunodeficiency, psychiatric, and other conditions which could interfere with the interpretation of the study results or compromise the health of the volunteers History of diabetes mellitus or cancer (except basal cell carcinoma of the skin) History of arrhythmias or prolonged QT-interval Positive family history in 1st and 2nd degree relatives for cardiac disease < 50 years old An estimated, ten year risk of fatal cardiovascular disease of ≥5%, as estimated by the Systematic Coronary Risk Evaluation (SCORE) system Clinically significant abnormalities in electrocardiogram (ECG) at screening